The largest database of trusted experimental protocols

Eclipse treatment planning system

Manufactured by Agilent Technologies
Sourced in United States, Germany, Canada

The Eclipse treatment planning system is a software tool designed for radiation therapy planning. It provides medical professionals with the capabilities to create and optimize treatment plans for cancer patients undergoing radiation therapy. The core function of the Eclipse system is to facilitate the planning and simulation of radiation treatment procedures.

Automatically generated - may contain errors

191 protocols using eclipse treatment planning system

1

RapidArc Treatment for Low-Risk Prostate Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ten low-risk prostate cancer cases treated with RapidArc technique were included in this study. All patients were treated at West Hills Radiation Therapy Center, Vantage Oncology, California, USA, and this study was approved by the Research and Ethical Committee of the institution. Patients were immobilized in a Vac-Lok system (CIVCO Medical Solutions, Kalona, Iowa) and all patients were instructed to maintain a full bladder during CT simulation process. The CT scans were acquired with 512 × 512 pixels at 0.25 cm slice using General Electric light speed CT scanner (GE Health-care, Milwaukee, WI). The clinical target volume (CTV) comprised of prostate and proximal seminal vesicles as well as organs at risks (OARs) such as rectum, bladder, and femoral heads were delineated on the axial CT images in the Eclipse treatment planning system (TPS) (Varian Medical Systems, Palo Alto, CA). The planning target volume (PTV) was created from the CTV by a uniform expansion of 5 mm in all directions.
+ Open protocol
+ Expand
2

Optimized VMAT Radiotherapy Planning

Check if the same lab product or an alternative is used in the 5 most similar protocols
All cases were planned according to the clinical dose prescription of 60 Gy in 30 fractions based on the ESTRO-EANO guidelines [28 (link)] in the Eclipse treatment planning system (TPS) V15.06.05 (Varian Medical Systems, Palo Alto). All OARs were subject to a dose constraint, which, according to a priority list, could or could not be compromised (Table 1). All plans used a volumetric arc technique (VMAT) with a double full co-planar arc with 6 MV beams containing a flattening filter. The plans were optimized with the photon optimizer, and doses were calculated with the Anisotropic Analytical Algorithm [29 (link)]. After dose calculation, the dose was normalized so that 50% of the PTV was covered by 100% of the prescribed dose, according to the institutional clinical guidelines.
+ Open protocol
+ Expand
3

Optimized Carbon Ion Treatment Plans

Check if the same lab product or an alternative is used in the 5 most similar protocols
Carbon ion treatment plans were created on the average intensity CT (planning CT) image of the 4D-CT for each patient. Each plan included two orthogonal radiation fields with a total prescription dose of 60 Gy delivered in 4 fractions. Treatment plan optimization was performed to obtain the optimal intensity of carbon ions for a given number of spots, for individual patient cases. Optimization was conducted on the planning CT using the Monte Carlo dose calculation and optimization package named goCMC25 (link), integrated into the Varian Eclipse treatment planning system (TPS)32 . The result of the optimization process was an optimized biological dose distribution on individual respiratory phase of the 4D-CT as well as 4D-CBCT for each patient.
+ Open protocol
+ Expand
4

IMRT Planning Using Eclipse TPS

Check if the same lab product or an alternative is used in the 5 most similar protocols
All IMRT plans were generated using the Eclipse Treatment Planning System (TPS) (v8.6; Varian Medical Systems, Palo Alto, CA, USA). Beam and collimator angles were chosen at the discretion of the radiation therapist and utilised five to seven coplanar static step-and-shoot fields.
Optimisation parameters were set according to departmental protocol and used physical/dose–volume-based objectives. OAR and non-target tissue (NTT) dose constraint objectives were used to reduce OAR maximum doses and hot spots outside the PTV respectively. Inhomogeneity corrections were applied and dose–volume histogram (DVH) data were generated. Final calculations were made using Eclipse AAA algorithm version 8.6 on an Elekta Synergy beam model using 1 centimetre (cm) multileaf collimators (MLC).
+ Open protocol
+ Expand
5

Comparative Dosimetric Analysis of IMRT, VMAT, and CyberKnife

Check if the same lab product or an alternative is used in the 5 most similar protocols
The Varian Eclipse treatment planning system (TPS) was used to prepare the two dynamic techniques (IMRT and VMAT) with an anisotropic analytical algorithm (AAA). The IMRT plans consisted of nine sliding window beams (0°, 40°, 80°, 120°, 160°, 200°, 240°, 280° and 320°). The VMAT plans had four partial arcs (235–125 collimator 30 and 330 clockwise arcs, 125–235 collimator 30 and 330 contraclockwise arcs). Both plans were calculated for 6 MV beam as it was only one output energy for CyberKnife. It was important to compare IMRT and VMAT under the most similar conditions to CK. Additional artificial structures were created to prepare a more suitable and conformal treatment plan.
Figure 1 shows the dose distributions for a patient on a transversal scan showing the IMRT (Figure 1A) and VMAT (Figure 1B) treatment plans. Figure 1C shows the CyberKnife plan for the same patient.
+ Open protocol
+ Expand
6

NSCLC Tumor Motion Management Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Approval from our institutional review board was obtained to utilize 90 clinically treated patients’ treatment plans for peripherally located early stage, NSCLC tumors that met the criteria set forth by RTOG‐0618. Motion management for these patients was primarily performed using abdominal compression unless the patient presented with a comorbidity that did not allow for compression, in these cases a 4D‐CT scan was performed. A gross tumor volume (GTV) was delineated in a lung window and a planning target volume (PTV) was created with added margins of 1.0 cm superior/inferior and 0.5 cm laterally per protocol guidelines. With the 4D‐CT scan, the PTV was generated using a 0.5 cm isotropic margin around the internal target volume (ITV). OARs were contoured per RTOG‐0618 guidelines. Clinical non‐coplanar VMAT plans were created in Varian’s Eclipse treatment planning system (TPS) on a Truebeam Linac (Varian Medical Systems, Palo Alto, CA). Details of patient set up have previously been published elsewhere.7 All patients received a total dose of 54 Gy in 3 fractions prescribed to the 70‐80% isodose line.
+ Open protocol
+ Expand
7

Characterizing PSMA-negative/FDG-positive Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
All patients enrolled in the LuPSMA prospective randomised trial (ID: ANZCTR12615000912583) at our institution but excluded due to discordance between 68Ga-PSMA-11 and 18F-FDG PET distribution were considered for inclusion (12 (link)). Patients were included in this retrospective study based on the presence of PSMA-negative/FDG-positive tumours. Images were acquired with GE Discovery PET/CT scanners (Model 690 or 710, General Electric Medical System, Milwaukee, USA).
Any FDG tumour uptake must be at the same spatial location as PSMA-avidity to be eligible for LuPSMA treatment. To verify this eligibility condition, non-physiological uptake was determined independently on the PSMA and FDG PET scans using liver-based threshold method. This exercise was completed by nuclear medicine physicians at the screening stage and resulted on a structure containing all tumour uptakes in each PET scan. These images and structures were retrospectively reviewed in this study. Images and structure sets of these patients were imported to the Eclipse treatment planning system (TPS) for gross tumour volume (GTV) delineation (v16.1, Varian Medical Systems, Palo Alto, USA). PET uptake was characterised from the standardised uptake value (SUV) normalised by body weight, to allow interpatient comparison.
+ Open protocol
+ Expand
8

Evaluating Breast Cancer WBRT Plans

Check if the same lab product or an alternative is used in the 5 most similar protocols
This retrospective study utilized thirty anonymized planning computed tomography (CT) datasets of early-stage female breast cancer patients previously treated with WBRT. To maintain diversity of breast sizes and shapes, 13 right-sided and 17 left-sided cases with various breast volumes and separations were selected (Table 1). Every identifiable patient data was replaced with unique numbers as part of de-identification step, according to the centre’s ethics protocol.
Planning CT datasets were acquired using Philips CT Big Bore (Philips Healthcare, Best, The Netherlands) with patients lying supine on a lift-up board and arms raised above the head. Each slice of acquired CT datasets was 3 mm in thickness. Image registration and delineation of gross tumour volume (GTV), PTV and OARs were performed using Eclipse Treatment Planning System (TPS) (version 13.6.23; Varian Medical Systems, Palo Alto, CA, USA). GTV and PTV were contoured by the radiation oncologist. Contoured OARs included contralateral breast (CB), heart, liver, left lung, right lung, and total bilateral lungs. Lung volumes were contoured using auto-threshold function of the planning system. Heart volume was contoured based the heart atlas guidelines. Both CB and liver were delineated based on the visible breast and liver tissues, respectively.
+ Open protocol
+ Expand
9

Lung Cancer Treatment Planning Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols
Patients in our cohort were scanned for treatment planning using Bright Speed 16 (GE Healthcare, Milwaukee, WI, USA) or SOMATOM Definition Flash AS (Siemens Healthcare, Erlangen, Germany) with a pixel size of <1.0 mm and a slice thickness of <2.5 mm.
We used either an analytical anisotropic algorithm or an Acuros XB dose calculation algorithm equipped in an Eclipse treatment planning system (TPS; Varian Medical Systems, Palo Alto, CA, USA) with a calculation grid of 2 mm. The number of patients treated with the Varian CL2100, CLINAC iX, and TrueBeam STx were 41, 109, and 3, respectively. The dose to normal lung was constrained within V5Gy < 65%, V20Gy < 35%, and MLD < 20 Gy, considering the RTOG0617 protocol [13 (link)] and while maintaining an adequate target volume coverage at the time the treatment plans were created.
Both cDVH and dDVH were computed from a dose–volume curve calculated using CT images, a structure set, and calculated dose exported from the Eclipse TPS in-house using MATLAB (MathWorks, Natick, MA, USA). cDVH features, including cV5Gy and cV10Gy–cV60Gy (in 10-Gy increments), and MLD, were also computed. Each dDVH feature was calculated between 5 and 60 Gy with dose bins of 2–8 Gy in 2-Gy increments (resulting in four patterns).
+ Open protocol
+ Expand
10

Evaluation of RTOG1308 Treatment Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols
Data from 210 patients enrolled in RTOG1308 at the time of this study were evaluated according to the IROC QA procedure. The treatment arm (photon or proton), the technique (passive scattering (PS) or intensity-modulated proton therapy (IMPT)), the type of treatment machine, and the dosimetric review in accordance with protocol dose constraints (per protocol: score 1, variation acceptable: score 2, and deviation unacceptable: score 3) were all collected. Table 1 summarizes the protocol’s dosimetric constraints for performing the initial plan quality review. The review revealed that there were no deviation unacceptable cases and five score 2 cases among all IMPT cases; 5 deviation unacceptable cases and 9 variation acceptable cases among all PS cases; and 4 deviation unacceptable cases and 6 variation acceptable cases among all photon cases.
Following the initial assessment, 130 patient data sets were chosen for this investigation. Fifty score 1 photon cases were randomly selected for model training. Eighty patients were selected as testing cases, and all cases of score 2 and score 3 were included with preferences. Among the 80 testing cases, 20 received IMPT, 20 received PS, and 40 received photon treatments. DICOM CT and RT structures of these 130 patients were imported into Eclipse Treatment Planning System (TPS) (Varian Medical Systems, Palo Alto, CA, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!